• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

银屑病关节炎的管理步骤:临床医生指南。

Steps in the management of psoriatic arthritis: a guide for clinicians.

机构信息

Department of Internal Medicine, Section of Rheumatology, LSU Health Sciences Center at New Orleans, New Orleans, LA, USA.

出版信息

Ther Adv Chronic Dis. 2012 Nov;3(6):259-69. doi: 10.1177/2040622312459673.

DOI:10.1177/2040622312459673
PMID:23342240
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3539260/
Abstract

Psoriatic arthritis is a common systemic inflammatory disorder, which in addition to skin and nail involvement may be associated with peripheral and axial joint involvement, enthesitis, dactylitis, and important comorbidities - especially cardiovascular morbidity. Better insights into the involved pathogenic mechanisms have resulted in an improved therapeutic armamentarium, which targets key pathways in its pathogenesis. This has resulted in significant clinical responses to newer therapeutic agents, especially those directed at inhibition of tumor necrosis factor α. Biological therapy leads to significant levels of remission, improved quality of life, and retards or improves structural radiological damage.

摘要

银屑病关节炎是一种常见的系统性炎症性疾病,除皮肤和指甲受累外,还可能与外周和中轴关节受累、肌腱端炎、指(趾)炎和重要的合并症(特别是心血管发病率)相关。对相关发病机制的深入了解导致了治疗手段的改进,这些手段针对其发病机制中的关键途径。这导致对新型治疗药物的显著临床反应,尤其是那些针对肿瘤坏死因子 α 抑制的药物。生物治疗可达到显著的缓解水平,提高生活质量,并延缓或改善结构影像学损伤。

相似文献

1
Steps in the management of psoriatic arthritis: a guide for clinicians.银屑病关节炎的管理步骤:临床医生指南。
Ther Adv Chronic Dis. 2012 Nov;3(6):259-69. doi: 10.1177/2040622312459673.
2
Infliximab in psoriasis and psoriatic arthritis.英夫利昔单抗治疗银屑病和银屑病关节炎。
BioDrugs. 2013 Jan;27 Suppl 1:13-23. doi: 10.1007/BF03325638.
3
Role of Agents other than Tumor Necrosis Factor Blockers in the Treatment of Psoriatic Arthritis.肿瘤坏死因子阻滞剂以外的药物在银屑病关节炎治疗中的作用
J Rheumatol Suppl. 2015 Nov;93:79-81. doi: 10.3899/jrheum.150643.
4
The pathogenesis of psoriatic arthritis.银屑病关节炎的发病机制。
Lancet. 2018 Jun 2;391(10136):2273-2284. doi: 10.1016/S0140-6736(18)30830-4. Epub 2018 Jun 1.
5
Treatment of psoriatic arthritis with biological agents.生物制剂治疗银屑病关节炎
Semin Cutan Med Surg. 2010 Mar;29(1):56-62. doi: 10.1016/j.sder.2010.01.004.
6
Clinical features of psoriatic arthritis.银屑病关节炎的临床特征。
Best Pract Res Clin Rheumatol. 2021 Jun;35(2):101670. doi: 10.1016/j.berh.2021.101670. Epub 2021 Mar 17.
7
Psoriatic arthritis for dermatologists.皮肤科医生须知的银屑病关节炎
J Dermatolog Treat. 2020 Nov;31(7):662-679. doi: 10.1080/09546634.2019.1605142. Epub 2019 May 7.
8
[Spectrum of psoriatic conditions].[银屑病相关病症谱]
Ned Tijdschr Geneeskd. 2019 Jul 29;163:D3936.
9
Axial psoriatic arthritis: An update for dermatologists.轴向银屑病关节炎:皮肤科医生的最新进展。
J Am Acad Dermatol. 2021 Jan;84(1):92-101. doi: 10.1016/j.jaad.2020.05.089. Epub 2020 Jul 31.
10
Enthesitis and its relationship with disease activity, functional status, and quality of life in psoriatic arthritis: a multi-center study.银屑病关节炎中附着点炎及其与疾病活动度、功能状态和生活质量的关系:一项多中心研究。
Rheumatol Int. 2020 Feb;40(2):283-294. doi: 10.1007/s00296-019-04480-9. Epub 2019 Nov 26.

引用本文的文献

1
Psoriatic arthritis in transition: cytokine signaling, immune dysregulation, and therapeutic innovation.转型期的银屑病关节炎:细胞因子信号传导、免疫失调与治疗创新
Inflammopharmacology. 2025 Jul 25. doi: 10.1007/s10787-025-01865-0.
2
Psoriatic arthritis among Egyptian patients with psoriasis attending the dermatology clinic: prevalence, comorbidities, and clinical predictors.埃及皮肤科门诊银屑病患者中的银屑病关节炎:患病率、合并症及临床预测因素
Reumatologia. 2021;59(6):394-401. doi: 10.5114/reum.2021.112238. Epub 2022 Jan 5.
3
Ixekizumab, with or without concomitant methotrexate, improves signs and symptoms of PsA: week 52 results from Spirit-P1 and Spirit-P2 studies.无论是否联用甲氨蝶呤,司库奇尤单抗均可改善银屑病关节炎的体征和症状:SPIRIT-P1和SPIRIT-P2研究的第52周结果
Arthritis Res Ther. 2021 Jan 27;23(1):41. doi: 10.1186/s13075-020-02388-5.
4
Patient-reported outcomes data in patients with psoriatic arthritis from a randomised trial of etanercept and methotrexate as monotherapy or in combination.接受依那西普和甲氨蝶呤单药或联合治疗的银屑病关节炎患者的患者报告结局数据:一项随机试验结果
RMD Open. 2021 Jan;7(1). doi: 10.1136/rmdopen-2020-001484.
5
Long-term effectiveness and safety of infliximab, golimumab and ustekinumab in patients with psoriatic arthritis from a Canadian prospective observational registry.来自加拿大前瞻性观察登记处的银屑病关节炎患者使用英夫利昔单抗、戈利木单抗和优特克单抗的长期疗效和安全性。
BMJ Open. 2020 Aug 13;10(8):e036245. doi: 10.1136/bmjopen-2019-036245.
6
Secukinumab: a promising therapeutic option in spondyloarthritis.司库奇尤单抗:脊柱关节炎中一种有前景的治疗选择。
Clin Rheumatol. 2016 Sep;35(9):2151-61. doi: 10.1007/s10067-016-3350-6. Epub 2016 Jul 20.
7
Macrophage migration inhibitory factor (MIF) promoter polymorphisms (-794 CATT5-8 and -173 G>C): association with MIF and TNFα in psoriatic arthritis.巨噬细胞移动抑制因子(MIF)启动子多态性(-794 CATT5-8和-173 G>C):与银屑病关节炎中MIF和TNFα的关联
Int J Clin Exp Med. 2014 Sep 15;7(9):2605-14. eCollection 2014.

本文引用的文献

1
Pathogenesis of spondyloarthritis: autoimmune or autoinflammatory?脊柱关节炎的发病机制:自身免疫还是自身炎症?
Curr Opin Rheumatol. 2012 Jul;24(4):351-8. doi: 10.1097/BOR.0b013e3283534df4.
2
FCGR2A/CD32A and FCGR3A/CD16A variants and EULAR response to tumor necrosis factor-α blockers in psoriatic arthritis: a longitudinal study with 6 months of followup.FCGR2A/CD32A 和 FCGR3A/CD16A 变体与银屑病关节炎对肿瘤坏死因子-α 阻滞剂的 EULAR 反应:一项具有 6 个月随访的纵向研究。
J Rheumatol. 2012 May;39(5):1035-41. doi: 10.3899/jrheum.110980. Epub 2012 Apr 1.
3
Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis.抗白细胞介素-17 单克隆抗体依奇珠单抗治疗慢性斑块状银屑病。
N Engl J Med. 2012 Mar 29;366(13):1190-9. doi: 10.1056/NEJMoa1109997.
4
Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis.布罗达单抗,一种用于治疗银屑病的抗白细胞介素-17 受体抗体。
N Engl J Med. 2012 Mar 29;366(13):1181-9. doi: 10.1056/NEJMoa1109017.
5
Cytokine-based therapy in psoriasis.基于细胞因子的银屑病治疗。
Clin Rev Allergy Immunol. 2013 Apr;44(2):173-82. doi: 10.1007/s12016-012-8306-2.
6
Psoriatic arthritis.银屑病关节炎。
Best Pract Res Clin Rheumatol. 2012 Feb;26(1):147-56. doi: 10.1016/j.berh.2012.01.003.
7
A cutting edge overview: psoriatic disease.前沿综述:银屑病。
Clin Rev Allergy Immunol. 2013 Apr;44(2):109-13. doi: 10.1007/s12016-012-8309-z.
8
A randomized placebo-controlled trial of methotrexate in psoriatic arthritis.一项关于甲氨蝶呤治疗银屑病关节炎的随机安慰剂对照试验。
Rheumatology (Oxford). 2012 Aug;51(8):1368-77. doi: 10.1093/rheumatology/kes001. Epub 2012 Feb 17.
9
Safety of anti-TNFα agents in the treatment of psoriasis and psoriatic arthritis.抗 TNF-α 制剂治疗银屑病和银屑病关节炎的安全性。
Immunopharmacol Immunotoxicol. 2012 Aug;34(4):548-60. doi: 10.3109/08923973.2011.653646. Epub 2012 Feb 2.
10
Apremilast mechanism of action and application to psoriasis and psoriatic arthritis.阿普米司特的作用机制及其在银屑病和银屑病关节炎中的应用。
Biochem Pharmacol. 2012 Jun 15;83(12):1583-90. doi: 10.1016/j.bcp.2012.01.001. Epub 2012 Jan 10.